Expert Pitch

Russian biologist explains recent findings regarding coronavirus structure

MOSCOW (MIPT) — The atomic structure of the novel coronavirus envelope has explained why it is exceptionally contagious. Its structural features make it much easier for the Chinese coronavirus to bind to target receptors, compared with the previously known SARS pathogen.

Molecular biologists in the U.S. have obtained the first 3D photos of the proteins on the surface of the coronavirus SARS-CoV-2, which is the cause of the pneumonia outbreak in China. According to the authors of the paper published in the bioRxiv online preprint repository, new findings are helpful for creating the vaccine and drugs against the disease.

Pavel Volchkov, who heads the Genome Engineering Lab at the Moscow Institute of Physics and Technology is available for comment on the coronavirus.

Q: What are the benefits of knowing the structure of the 3D viral envelope?

A: The 3D structure is helpful for understanding the protein interactions inside the virus. In particular, the new study reports that the structure clarifies how the virus binds to its receptor, how it infiltrates the cell, how the viral RNA is delivered and concealed from the host.

In the case of an infection, the numerous viral RNAs are transcribed (expressed), leading to the synthesis of other RNAs — messenger RNAs — and therefore proteins. So we gain insights into the molecular mechanisms at play, that is, exactly how the infection occurs.

Q: How can this help to develop a vaccine?

A: By figuring out the structure of the viral particle, we understand which protein components — the so-called epitopes exposed on the surface — we can use to develop a vaccine. In doing that, we rely on those parts that experience the most effective immune response. Usually, a combination of epitopes is used, prioritizing those exposed on the surface and triggering the production of antibodies, which ultimately bind the viral particles. This means that a vaccine does not actually target the virus as a whole, or all of its genes, but certain protein subunits.

Q: Why is this pathogen so contagious?

A: The researchers have shown that while the SARS-CoV-2 structure is very similar to that of the previous coronavirus, the new one has a much higher affinity for a certain surface receptor. There is a stronger interaction between the virus and its target, making it more contagious. The pathogen effectively causes an infection with fewer viral particles.

The researchers have also concluded that the characteristic epitopes of the previous severe acute respiratory syndrome virus, for which antibodies are available, are not present in the new virus. As a result, a therapy based on antibodies against SARS is not applicable, which has already been confirmed on practice.

The only effective antibodies are those generated by the immune system of patients who recovered from a SARS-CoV-2 infection. Only they can be used in a serum based on plasma extracted from donor blood. These antibodies are mostly polyclonal and will target multiple epitope sites on the coronavirus surface.

Q: Is a pandemic possible?

A: The likelihood of a pandemic coronavirus scenario is low. For this to happen, the situation in China has to repeat in other countries. China has launched a large-scale campaign to prevent the epidemic. The outbreak epicenters have been closed down, and other nations’ health agencies are also stepping up epidemiologic protection measures. As of Feb. 20, Russia has temporarily banned Chinese citizens from entering the country.


Pavel Volchkov can be reached by contacting Varvara Bogomolova or Nicolas Posunko at the MIPT Press Office.

The MIPT website has more news about the research done at the Institute.

Filters close

Showing results

110 of 2539
Released: 13-Jul-2020 4:05 PM EDT
OADN & AACN Secure No-Cost Access to COVID-19 Screening Solution Until Vaccines Become Widely Available
Organization for Associate Degree Nursing (OADN)

OADN & AACN Secure No-Cost Access to COVID-19 Screening Solution Until Vaccines Become Widely Available

Newswise: Study suggests lymphoma drug acalabrutinib might offer a potential therapeutic approach for severe COVID-19 infection
Released: 13-Jul-2020 3:45 PM EDT
Study suggests lymphoma drug acalabrutinib might offer a potential therapeutic approach for severe COVID-19 infection
Hackensack Meridian Health

The mechanisms of action of acalabrutinib led to the hypothesis it might be effective in reducing the massive inflammatory response seen severe forms of COVID19. Indeed, it did provide clinical benefit in a small group of patients by reducing their inflammatory parameters and improving their oxygenation.

Newswise: National Virtual Biotechnology Laboratory Unites DOE Labs Against COVID-19
Released: 13-Jul-2020 3:40 PM EDT
National Virtual Biotechnology Laboratory Unites DOE Labs Against COVID-19
Department of Energy, Office of Science

To focus its efforts against the COVID-19 pandemic, DOE is bringing the national laboratories together into the National Virtual Biotechnology Laboratory.

Newswise: Key Insights from Swedish Casino that Remained Open During COVID-19
Released: 13-Jul-2020 3:40 PM EDT
Key Insights from Swedish Casino that Remained Open During COVID-19
University of Nevada, Las Vegas (UNLV)

As casinos in Las Vegas enter the second month of reopening since the COVID-19 pandemic took hold, UNLV gaming researchers say they can draw upon insights from industry collaborators in Sweden, a country that took a more open approach to the crisis compared to other governments.

Released: 13-Jul-2020 3:05 PM EDT
Asymptomatic Transmission and Reinfection of COVID: Live Event for July 16, 2PM EDT

Emerging data shows more risk of asymptomatic transmission and reinfection with COVID than previously thought. Experts will discuss these findings and what are the implications for managing the pandemic. Media are invited to attend and ask questions.

Released: 13-Jul-2020 2:40 PM EDT
Engineered llama antibodies neutralize COVID-19 virus
Rosalind Franklin Institute

Antibodies derived from llamas have been shown to neutralise the SARS-CoV-2 virus in lab tests, UK researchers announced today.

Released: 13-Jul-2020 1:25 PM EDT
1 in 3 young adults may face severe COVID-19
University of California, San Francisco (UCSF)

As the number of young adults infected with the coronavirus surges throughout the nation, a new study by researchers at UCSF Benioff Children's Hospitals indicates that youth may not shield people from serious disease.

Released: 13-Jul-2020 12:25 PM EDT
Scientists discover key element of strong antibody response to COVID-19
Scripps Research Institute

A team led by scientists at Scripps Research has discovered a common molecular feature found in many of the human antibodies that neutralize SARS-CoV-2, the coronavirus that causes COVID-19.

Released: 13-Jul-2020 11:15 AM EDT
UTHealth joins study of blood pressure medication’s effect on improving COVID-19 outcomes
University of Texas Health Science Center at Houston

An interventional therapy aimed at improving survival chances and reducing the need for critical care treatment due to COVID-19 is being investigated by physicians at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is underway at Memorial Hermann and Harris Health System’s Lyndon B. Johnson Hospital.

Showing results

110 of 2539